Equity Profile

ORKA

Oruka Therapeutics, Inc.

Health CareBiotechnology$5.1B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to address unmet medical needs....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Oruka is managing its costs and revenues.

Expected EPS is not available.

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and attract new customers.

Expected revenue is not available.

Wall Street expectations, options signals, track record, and call prep available with Pro.

ORKA Q2-2026 Earnings Preview

Context

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to address unmet medical needs. Operating in the health care sector, Oruka is part of a growing industry that seeks to leverage advancements in science and technology to improve patient outcomes.

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

In the last quarter, Oruka reported an EPS of -$0.48, which was better than the expected -$0.52, marking an 8.4% surprise. However, the stock fell by 2.27% the following day, reflecting market concerns despite the positive earnings surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as there are no analyst estimates available, and the stock has shown volatility following past earnings reports. Investors will be watching closely for any signs of revenue growth or improvements in EPS.

Bull Case

If Oruka can continue to beat EPS estimates and show signs of revenue growth, it may signal a turnaround in investor sentiment, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or shows continued losses, it could lead to further declines in stock price, especially given the high implied volatility in the options market.

Key Metrics to Watch

EPS

Expected EPS is not available.

Earnings per share is a key indicator of profitability and will show how well Oruka is managing its costs and revenues.

Revenue Growth

Expected revenue is not available.

Revenue growth will indicate the company's ability to expand its market presence and attract new customers.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of beating EPS estimates, this number will be crucial for investor confidence and stock performance.

What are the revenue figures for this quarter?

Revenue growth is essential for assessing the company's market position and future potential, making it a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Oruka's potential for revenue growth due to its innovative pipeline, which could lead to stronger-than-expected demand for its therapies.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

Options pricing suggests a significant move, indicating that traders are expecting volatility that could favor the upside.

Key Risk

If revenue growth exceeds expectations, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Oruka can sustain its recent trend of beating EPS estimates while also addressing revenue growth.

Bull Confirmed If

A positive EPS of -$0.40 or better would confirm the bull case, indicating improved financial health.

Bear Confirmed If

An EPS worse than -$0.55 would confirm the bear case, suggesting ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±35.62%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect a lot of volatility around the earnings report.

Options are pricing ±35.6% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.3%

Calls (600)P/C Ratio: 0.13Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +2.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats expectations, history suggests the stock could see an average 1-day move of around -2.31%, but this could lead to a more positive sentiment overall.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the news, leading to cautious trading.

Miss

If the company misses expectations, history suggests a potential decline, with an average 1-day move of -2.27% following previous misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on any new product developments or clinical trial results.
2Management's outlook on revenue growth and market expansion.
3Updates on cost management strategies and their impact on EPS.
4Any commentary on competitive positioning within the biotechnology sector.
5Insights into future guidance or strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Oruka Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to address unmet medical needs....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Oruka is managing its costs and revenues.

Expected EPS is not available.

Revenue Growth

Revenue growth will indicate the company's ability to expand its market presence and attract new customers.

Expected revenue is not available.

Wall Street expectations, options signals, track record, and call prep available with Pro.

ORKA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 4Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.82%

Avg Stock Reaction

-2.31%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Oruka can continue to beat EPS estimates and show signs of revenue growth, it may signal a turnaround in investor sentiment, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or shows continued losses, it could lead to further declines in stock price, especially given the high implied volatility in the options market.

Key Metrics to Watch

EPS

Expected EPS is not available.

Earnings per share is a key indicator of profitability and will show how well Oruka is managing its costs and revenues.

Revenue Growth

Expected revenue is not available.

Revenue growth will indicate the company's ability to expand its market presence and attract new customers.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of beating EPS estimates, this number will be crucial for investor confidence and stock performance.

What are the revenue figures for this quarter?

Revenue growth is essential for assessing the company's market position and future potential, making it a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Oruka's potential for revenue growth due to its innovative pipeline, which could lead to stronger-than-expected demand for its therapies.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating stronger operational performance than anticipated.

Options pricing suggests a significant move, indicating that traders are expecting volatility that could favor the upside.

Key Risk

If revenue growth exceeds expectations, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Oruka can sustain its recent trend of beating EPS estimates while also addressing revenue growth.

Bull Confirmed If

A positive EPS of -$0.40 or better would confirm the bull case, indicating improved financial health.

Bear Confirmed If

An EPS worse than -$0.55 would confirm the bear case, suggesting ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±35.62%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect a lot of volatility around the earnings report.

Options are pricing ±35.6% while ORKA has averaged ±2.5% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

67.3%

Calls (600)P/C Ratio: 0.13Puts (6K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Oruka beats expectations, history suggests the stock could see an average 1-day move of around -2.31%, but this could lead to a more positive sentiment overall.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the news, leading to cautious trading.

Miss

If the company misses expectations, history suggests a potential decline, with an average 1-day move of -2.27% following previous misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on any new product developments or clinical trial results.
2Management's outlook on revenue growth and market expansion.
3Updates on cost management strategies and their impact on EPS.
4Any commentary on competitive positioning within the biotechnology sector.
5Insights into future guidance or strategic initiatives.